Enovis Corporation (ENOV) Stock

Enovis Corporation (ENOV) is a Healthcare stock trading at $26.17 (as of 2026-08-20), with a market capitalization of $1.51B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Understand Enovis Corporation: how it makes money

Enovis Corporation develops, manufactures, and distributes orthopedic and musculoskeletal medical device products, selling to orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.

With gross margin at 62.0% and operating margin at 1.1%, the profit model depends on converting high product gross profit into operating profit through tight operating cost control.

Business quality (Weak): The provided operating KPI set includes Revenues Range and early case or adoption-style measures, but the segment detail is limited in the facts given, so investors mainly have headline margins and a narrow KPI view to judge performance.

Bull case

High product gross profitability: Gross margin is reported at 62.0%, suggesting the company can generate substantial gross profit from its medical device products.
Operating profitability is positive: Operating margin is reported at 1.1%, indicating the business is producing operating profit rather than only gross profit.

Bear case

Thin operating margin leaves less room for error: Operating margin is 1.1%, so small changes in operating costs or other operating pressures could have an outsized impact on results.
Limited segment visibility in the provided facts: Only total Net Sales style figures and a small set of KPIs are provided, which makes it harder to pinpoint what specific parts of the business are driving changes.

Valuation — source: SEC EDGAR (first-party)
Price	$26.17
Market Cap	$1.51B
Price / Book	1.02
Price / Sales	0.65
FCF Yield	-4.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.25B
Net Margin	-52.7%
Revenue Growth (YoY)	6.7%
EPS Growth (YoY)	39.0%
FCF Growth (YoY)	-129.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.34 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($226.05M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Damien McDonald
Employees	7,367
Country	US
IPO Date	2008-05-08

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.